SARS-CoV 2: Clinical Trials

16 trials for SARS-CoV 2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed. 16 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 216Completed 16
Phase 13Completed 3
Phase 31Completed 1

Follow SARS-CoV 2: new trials by email Literature Review of SARS-CoV 2 trials Research Report on SARS-CoV 2

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Favipiravir vs Hydroxychloroquine vs Control in COVID -19
Hydroxychloroquine, Favipiravir, Routine care for COVID-19 patients - SARS-CoV 2, COVID-19
Phase 2CompletedRoyal College of Surgeons in Ireland - Medical University of Bahrain1502020-08-112021-10-26
Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19
INO-4800, CELLECTRA® 2000, Saline-sodium citrate (SSC) buffer - Coronavirus Infection, SARS-CoV 2
Phase 1 / Phase 2CompletedInternational Vaccine Institute792020-07-152022-07-18
Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19
Melatonin intravenous, Placebo intravenous - COVID-19, SARS-CoV 2
Phase 2CompletedPharmamel S.L.182020-06-202021-03-18
The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
EIDD-2801, Placebo - SARS-CoV 2
Phase 2CompletedRidgeback Biotherapeutics, LP712020-06-162023-03-23
Convalescent Plasma to Limit SARS-CoV-2 Associated Complications
SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor - SARS-CoV 2
Phase 2CompletedJohns Hopkins University12252020-06-032023-06-02
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
Mavrilimumab, Placebo - COVID 19, SARS-CoV 2
Phase 2CompletedKristin Hudock12020-05-202024-12-09
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
Mavrilimumab, Placebos - COVID 19, SARS-CoV 2
Phase 2CompletedThe Cleveland Clinic402020-05-202021-05-13
Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19
XCEL-UMC-BETA, Placebo - COVID-19, SARS-CoV 2
Phase 1 / Phase 2CompletedBanc de Sang i Teixits262020-05-132023-01-26
A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
ArtemiC, Placebo - COVID-19, Corona Virus Infection
Phase 2CompletedMGC Pharmaceuticals d.o.o502020-05-082021-08-31
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
BAT + Calcifediol, BAT - SARS-CoV 2, COVID19
Phase 2CompletedMaimónides Biomedical Research Institute of Córdoba5172020-05-072023-03-03
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma - Corona Virus Infection, SARS-CoV 2
Phase 2CompletedUniversity of Virginia292020-05-052022-04-01
COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients
Povidone-Iodine Nasal Spray and Gargle - COVID-19, SARS-CoV 2
Phase 2CompletedNikita Gupta982020-04-292022-12-02
Clinical Trial of Sarilumab in Adults With COVID-19
Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA], Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA], Best available treatment - SARS-CoV 2, SARS
Phase 2CompletedMaimónides Biomedical Research Institute of Córdoba1202020-04-282021-07-07
Canakinumab in Covid-19 Cardiac Injury (The Three C Study)
Canakinumab Injection 600mg, Canakinumab Injection 300mg, Placebos - COVID-19, SARS-CoV 2
Phase 2CompletedThe Cleveland Clinic452020-04-242021-04-15
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection
Hyperimmune plasma, Standard of care for SARS-CoV-2 infection - SARS-CoV 2
Phase 1 / Phase 2CompletedAndalusian Network for Design and Translation of Advanced Therapies722020-04-232022-04-06
Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.
Melatonin 2mg, Placebo oral tablet - Covid19, SARS-CoV 2
Phase 2 / Phase 3CompletedInstituto de Investigación Hospital Universitario La Paz4502020-04-202021-11-23

Narrower conditions

COVID-19 (11)  ·  Coronavirus Infections (5)  ·  Pneumonia (3)  ·  Cytokine Release Syndrome (1)  ·  Respiratory Distress Syndrome (1)  ·  Severe Acute Respiratory Syndrome (1)

Broader conditions

Coronaviridae Infections (13)  ·  Infections (13)  ·  Nidovirales Infections (13)  ·  RNA Virus Infections (13)  ·  Virus Diseases (13)  ·  Lung Diseases (12)  ·  Respiratory Tract Diseases (12)  ·  Respiratory Tract Infections (12)  ·  Pneumonia, Viral (11)  ·  Pneumonia (9)  ·  Coronavirus Infections (8)  ·  Inflammation (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Respiration Disorders (1)

Interventions

COVID-19 Serotherapy (2)  ·  mavrilimumab (2)  ·  Buffers (1)  ·  Calcifediol (1)  ·  Hydroxychloroquine (1)  ·  Melatonin (1)  ·  Mouthwashes (1)  ·  Standard of Care (1)  ·  canakinumab (1)  ·  favipiravir (1)  ·  glycine N-choloyltransferase (1)  ·  molnupiravir (1)  ·  reluscovtogene ralaplasmid (1)  ·  sarilumab (1)

Sponsors

Maimónides Biomedical Research Institute of Córdoba (2)  ·  The Cleveland Clinic (2)  ·  Andalusian Network for Design and Translation of Advanced Therapies (1)  ·  Banc de Sang i Teixits (1)  ·  Instituto de Investigación Hospital Universitario La Paz (1)  ·  International Vaccine Institute (1)  ·  Johns Hopkins University (1)  ·  Kristin Hudock (1)  ·  MGC Pharmaceuticals d.o.o (1)  ·  Nikita Gupta (1)  ·  Pharmamel S.L. (1)  ·  Ridgeback Biotherapeutics, LP (1)  ·  Royal College of Surgeons in Ireland - Medical University of Bahrain (1)  ·  University of Virginia (1)

Countries

United States (7)  ·  Spain (6)  ·  Bahrain (1)  ·  India (1)  ·  Israel (1)  ·  South Korea (1)

Top investigators

Paul C Cremer, M. D. (2)  ·  Alberto M Borobia, MD, PhD (1)  ·  Alexandra E Kejner, MD (1)  ·  Antoni Torres, MD, PhD (1)  ·  Antonio J Carcas (1)  ·  Ashwin Balagopal, MD (1)  ·  David J Sullivan, MD (1)  ·  Eu Suk Kim, MD (1)  ·  Kristin Hudock, MD (1)

Results publications

PMID 33754144, PMID 32936949, PMID 33191263, PMID 33273742, PMID 34029377, PMID 34902262, PMID 34981068, PMID 35322077, PMID 35353960, PMID 36722044, PMID 37131659, PMID 38483534

NIH funding

R01AI152078 (1), U24TR001609 (1), UL1TR003098 (1)